Previous 10 | Next 10 |
LogicBio press release (NASDAQ:LOGC): FY GAAP EPS of -$1.24 beats by $0.08. Revenue of $5.41M (+56.8% Y/Y) beats by $0.56M. For further details see: LogicBio GAAP EPS of -$1.24 beats by $0.08, revenue of $5.41M beats by $0.56M
LogicBio Therapeutics Reports Full Year 2021 Financial Results and Provides Business Updates PR Newswire LEXINGTON, Mass. , March 4, 2022 /PRNewswire/ -- LogicBio® Therapeutics, Inc. (Nasdaq: LOGC), a clinical-stage genetic medicine company...
LogicBio Therapeutics (LOGC -2.5%) continues to trade lower as investors react to the FDA clinical hold imposed on its Phase 1/2 SUNRISE clinical trial for adeno-associated virus (AAV) genome editing therapy, LB-001, in children with methylmalonic acidemia (MMA). Noting the lack of clari...
Gainers: Palisade Bio (NASDAQ:PALI) +23%. Pharming Group (NASDAQ:PHAR) +14%. Entasis Therapeutics (NASDAQ:ETTX) +13%. Epizyme (NASDAQ:EPZM) +11%. IceCure Medical (NASDAQ:ICCM) +10%. Losers: LogicBio Therapeutics (NASDAQ:LOGC) -50%. Pardes Bios...
LogicBio Therapeutics (NASDAQ:LOGC) is trading ~25% lower in the pre-market after announcing that the FDA imposed a clinical hold on its Phase 1/2 SUNRISE clinical trial for its genome editing therapy LB-001 in children with methylmalonic acidemia (MMA). MMA is an inherited disorder...
LogicBio Therapeutics Provides Update on LB-001 Clinical Development Program - Company to host conference call and webcast today at 8:30 a.m. ET PR Newswire LEXINGTON, Mass. , Feb. 2, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq: LOGC), ...
LogicBio Therapeutics to Present at the H.C. Wainwright Bioconnect Conference PR Newswire LEXINGTON, Mass. , Jan. 4, 2022 /PRNewswire/ -- LogicBio Therapeutics, Inc. (Nasdaq:LOGC), a clinical-stage genetic medicine company, today announced that presiden...
LogicBio Therapeutics Provides Business Updates - SUNRISE Phase 1/2 interim data expected to be announced in 2Q 2022 - - New GeneRide™ development candidate nominated for the treatment of hereditary tyrosinemia type 1 - - Susan R. Kahn, leading advocate for patien...
LogicBio Therapeutics Reports Third Quarter 2021 Financial Results and Highlights Recent Company Milestones - Early clinical results from SUNRISE trial demonstrated first-ever in vivo genome editing in children - New preclinical data highlighting successful repopulation of d...
LogicBio Therapeutics Announces Successful Repopulation of Diseased Livers in Mice with Healthy Corrected Hepatocytes in Two New Indications Using GeneRide™ Genome Editing Technology - Data from mouse models in hereditary tyrosinemia type 1 and Wilson disease showed in vi...
News, Short Squeeze, Breakout and More Instantly...
LogicBio Therapeutics Inc. Company Name:
LOGC Stock Symbol:
NASDAQ Market:
LogicBio Therapeutics Inc. Website:
2024-05-27 03:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates PR Newswire - Pre-clinical results published in PLOS ONE demonstrating a single intravenous administration of mLB-001 in neonatal or adult MMA mice correlated with preventi...
NEW YORK, NY / ACCESSWIRE / October 20, 2022 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: KnowBe4, Inc. (NASDAQ:KNBE)'s s...